Background <p>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising an anticarcinoembryonic antigen (CEA) linked to an interleukin-2 (IL-2) variant. CA does not bind to CD25 (IL-2 receptor α) and was designed to maintain the T and natural killer (NK) cell stimulatory effect, while avoiding stimulating effects on regulatory T cells (Tregs). In mouse models, CA previously demonstrated superior tumor targeting to…
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer | | Melero, I., Steeghs, N., Lassen, U., Homicsko, K., Tabernero, J., Canamero, M., Roller, A., Duarte, J., Rossmann, E., Babitzki, G., Grabole, N., Watson, C., Habigt, C., Evers, S., Dejardin, D., Teichgräber, V., Charo, J.
Topics: cervical-cancer, targeted-therapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer